Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Faeth Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 40 | 34 | −6 |
| Shares | 3.15M | 2.32M | −831.7K (−26.4%) |
| Value | $45.8M | $22.7M | −$23.1M (−50.5%) |
New holders (3)
Institutions that held Faeth Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alps Advisors Inc | 40,286 | $393.0K | 0.00% |
| Alyeska Investment Group, L.P. | 40,000 | $390.0K | 0.00% |
| Banque Cantonale Vaudoise | 300 | $3.00K | 0.00% |
Sold out (9)
Institutions that held Faeth Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 375,000 | $5.45M |
| Falcon Edge Capital, LP | 213,658 | $3.10M |
| Balyasny Asset Management LLC | 27,603 | $401.0K |
| Davidson Kempner Capital Management LP | 26,000 | $376.0K |
| Serengeti Asset Management LP | 20,000 | $291.0K |
| Marshall Wace North America L.P. | 18,273 | $265.0K |
| Advisor Group Holdings, Inc. | 2,629 | $38.0K |
| STRS Ohio | 1,800 | $26.0K |
| Bank of Montreal | 270 | $4.00K |